Basit öğe kaydını göster

dc.contributor.authorAtasoy, Irem L.
dc.contributor.authorBilgic, Başar
dc.contributor.authorGunduz, Aysegul
dc.contributor.authorLohmann, Ebba
dc.contributor.authorGezen-Ak, Duygu
dc.contributor.authorDursun, Erdinc
dc.contributor.authorHanagasi, Haşmet Ayhan
dc.contributor.authorApaydin, Hulya
dc.contributor.authorYilmazer, Selma
dc.contributor.authorKiziltan, Gunes
dc.contributor.authorAraz, Omur Selin
dc.contributor.authorOnal, Burak
dc.contributor.authorAlaylioglu, Merve
dc.contributor.authorErtan, Sibel
dc.contributor.authorGurvit, Hakan
dc.contributor.authorUlutin, Turgut
dc.date.accessioned2021-03-06T08:08:15Z
dc.date.available2021-03-06T08:08:15Z
dc.identifier.citationDursun E., Gezen-Ak D., Hanagasi H. A. , Bilgic B., Lohmann E., Ertan S., Atasoy I. L. , Alaylioglu M., Araz O. S. , Onal B., et al., "The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease", Journal of Neuroimmunology, cilt.283, ss.50-57, 2015
dc.identifier.issn0165-5728
dc.identifier.otherav_df774b4a-9450-473b-885c-0d48835ac84d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/147212
dc.identifier.urihttps://doi.org/10.1016/j.jneuroim.2015.04.014
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84929601144&origin=inward
dc.description.abstract© 2015 Elsevier B.V.Alzheimer's disease (EOAD, LOAD), mild cognitive impairment (MCI), Parkinson's disease (PD) and healthy controls were included to determine the serum interleukin-1s (IL-1α, IL-1β), IL-6 and alpha-2-macroglobulin (α2M) levels using ELISA.IL-6 might be a significant contributor to the inflammatory response in LOAD. The MCI data indicate that IL-1s, α2M and BDNF are somehow related, and this relationship might allow MCI patients to be more similar to the healthy controls.A correlation analysis of multiple biomarkers in different neurodegenerative disorders might be more useful than determining the levels of a single cytokine in a single disorder.
dc.language.isoeng
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectSinirbilim ve Davranış
dc.subjectNEUROSCIENCES
dc.subjectİmmünoloji
dc.titleThe interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease
dc.typeMakale
dc.relation.journalJournal of Neuroimmunology
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume283
dc.identifier.startpage50
dc.identifier.endpage57
dc.contributor.firstauthorID6363


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster